Catriona Yale Akero Therapeutics, Inc. (AKRO) insider trading activity

Catriona Yale is Chief Development Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 91,488 shares of AKRO, which is worth approximately $4.84 Million. The most recent transaction as insider was on Nov 06, 2024, when has been sold 10,000 shares (Common Stock) at a price of $0.62 per share, resulting in proceeds of $6,200. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 91.5K

3.73% 3M change

20.49% 12M change

Total Value Held $4.84 Million

Catriona Yale Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 06 2024	BUY Exercise of conversion of derivative security	$6,200 $0.62 p/Share	10,000 Added 10.62%	84,158 Common Stock
Nov 01 2024	SELL Open market or private sale	$505,120 $32.62 p/Share	15,485 Reduced 17.27%	74,158 Common Stock
Nov 01 2024	BUY Exercise of conversion of derivative security	$326,733 $21.1 p/Share	15,485 Added 14.73%	89,643 Common Stock
Oct 30 2024	SELL Open market or private sale	$146,872 $32.53 p/Share	4,515 Reduced 5.74%	74,158 Common Stock
Oct 30 2024	BUY Exercise of conversion of derivative security	$95,266 $21.1 p/Share	4,515 Added 5.43%	78,673 Common Stock
Oct 15 2024	SELL Open market or private sale	$455,424 $30.72 p/Share	14,825 Reduced 16.45%	75,294 Common Stock
Oct 15 2024	BUY Exercise of conversion of derivative security	$9,191 $0.62 p/Share	14,825 Added 14.13%	90,119 Common Stock
Oct 14 2024	SELL Open market or private sale	$184,264 $30.03 p/Share	6,136 Reduced 7.64%	74,158 Common Stock
Oct 14 2024	BUY Exercise of conversion of derivative security	$3,100 $0.62 p/Share	5,000 Added 5.86%	80,294 Common Stock
Sep 20 2024	SELL Open market or private sale	$152,075 $27.65 p/Share	5,500 Reduced 6.81%	75,294 Common Stock
Sep 20 2024	BUY Exercise of conversion of derivative security	$3,410 $0.62 p/Share	5,500 Added 6.37%	80,794 Common Stock
Sep 18 2024	SELL Open market or private sale	$106,684 $27.56 p/Share	3,871 Reduced 4.89%	75,294 Common Stock
Sep 18 2024	BUY Exercise of conversion of derivative security	$2,400 $0.62 p/Share	3,871 Added 4.66%	79,165 Common Stock
Sep 17 2024	SELL Open market or private sale	$56,119 $27.55 p/Share	2,037 Reduced 2.63%	75,294 Common Stock
Sep 17 2024	BUY Exercise of conversion of derivative security	$1,262 $0.62 p/Share	2,037 Added 2.57%	77,331 Common Stock
Sep 16 2024	SELL Open market or private sale	$68,387 $27.52 p/Share	2,485 Reduced 3.19%	75,294 Common Stock
Sep 16 2024	BUY Exercise of conversion of derivative security	$1,540 $0.62 p/Share	2,485 Added 3.1%	77,779 Common Stock
Sep 10 2024	SELL Open market or private sale	$16,676 $26.18 p/Share	637 Reduced 0.84%	75,294 Common Stock
Sep 03 2024	SELL Open market or private sale	$26,201 $27.61 p/Share	949 Reduced 1.23%	75,931 Common Stock
Sep 03 2024	BUY Exercise of conversion of derivative security	$588 $0.62 p/Share	949 Added 1.22%	76,880 Common Stock
Aug 26 2024	SELL Open market or private sale	$143,052 $27.51 p/Share	5,200 Reduced 6.41%	75,931 Common Stock
Aug 26 2024	BUY Exercise of conversion of derivative security	$3,224 $0.62 p/Share	5,200 Added 6.02%	81,131 Common Stock
Aug 23 2024	SELL Open market or private sale	$243,668 $27.53 p/Share	8,851 Reduced 10.44%	75,931 Common Stock
Aug 23 2024	BUY Exercise of conversion of derivative security	$5,487 $0.62 p/Share	8,851 Added 9.45%	84,782 Common Stock
Jun 28 2024	BUY Grant, award, or other acquisition	$21,216 $19.94 p/Share	1,064 Added 1.38%	75,931 Common Stock

Catriona Yale

Chief Development Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Value

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO

Account